DARU-Journal of Pharmaceutical Sciences

Papers
(The H4-Index of DARU-Journal of Pharmaceutical Sciences is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Hybrid derivatives containing dimethyl fumarate and benzothiazole scaffolds for the potential treatment of multiple sclerosis; in silico & in vivo study42
New psychoactive substances: a multidisciplinary review of challenges and their diverse character24
Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation22
Co-delivery of SN38 and rapamycin albumin bound nanoparticles against breast Cancer20
Lipid nanoparticles for gene therapy in ocular diseases19
Colistin induced acute kidney injury in critically ill children: a prospective study utilizing RIFLE criteria19
Effect of vitamins C and E on cancer survival; a systematic review18
Dispersive micro-solid phase extraction based on two MOFs as highly effective adsorbents for analysis of nilotinib in plasma and wastewater18
Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report16
Management and control of intraocular pressure applying macitentan hydrogel film formulation: improved effect of surfactant and cosurfactant system15
Stearyl amine tailored spanlastics embedded within tetronic® nanogel for boosting the repurposed anticancer potential of mebendazole: formulation, in vitro profiling, cytotoxicity assessment, and in v14
Oral regimen for high dose methotrexate urine alkalinization: a systematic review and meta-analysis14
Impact of concerning excipients on animal safety: insights for veterinary pharmacotherapy and regulatory considerations13
Structure based exploration of mitochondrial alpha carbonic anhydrase inhibitors as potential leads for anti-obesity drug development13
Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population13
Evaluation of clinical and safety outcomes of generic tacrolimus (Suprotac $$\circledR$$) versus branded tacrolimus (Prograf $$\circledR$$) in de novo liver transplant patients: a randomized clinical 13
0.073188066482544